Moderne Diagnostik und standardisiertes Therapiemonitoring beim malignen Melanom

详细信息    查看全文

• 作者：PD. Dr. T. Persigehl ; Dr. T. D. Poeppel
• 关键词：SchlüsselwörterStrukturierte Befundung ; Therapiemonitoring ; Response ; Kriterien ; RECIST 1.1 ; irRECIST 1.1 ; PERCIST 1.0
• 刊名：Forum
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：31
• 期：5
• 页码：372-385
• 全文大小：2,971 KB
• 刊物主题：Oncology; Surgical Oncology; Internal Medicine; Hematology; Gynecology;
• 出版者：Springer Berlin Heidelberg
• ISSN：2190-9784
• 卷排序：31

文摘

Radiological and magnetic resonance imaging allow sensitive whole body diagnostics of malignant melanoma within the framework of extended diagnostics, therapy monitoring and follow-up care. Structured reporting is in this context an established method for clear and objective documentation of individual tumors, which seems to be necessary for therapy control. The “response evaluation criteria in solid tumors” (RECIST) currently represent the most well-established morphological criteria for standardized assessment of response to therapy of solid tumors under cytostatic and cytotoxic tumor therapy. However, with the introduction of novel molecular drugs the limitations of these size-based criteria became obvious due to response patterns which are not reflected by classical response criteria. Thus, for the evaluation of modern immunotherapeutic agents special morphological “immune-related response criteria” (irRECIST) were developed. At the same time metabolic therapy monitoring by “positron emission tomography (PET) response criteria in solid tumors” (PERCIST) was standardized in the field of molecular imaging. This review article describes the principles of the most important diagnostic and response criteria for malignant melanoma.